Dexrazoxane for the treatment of chemotherapy-related side effects
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Cancer Management and Research |
Vol/bind | 6 |
Sider (fra-til) | 357-63 |
Antal sider | 7 |
ISSN | 1179-1322 |
DOI | |
Status | Udgivet - 2014 |
ID: 247891061